BMO Capital analyst Keith Tapper reiterated an Outperform rating and $60.00 price target on Neurogene (NASDAQ: NGNE).The analyst commented, "The ...

(Premium-only article. Please sign in or upgrade to SI Premium to view.)

Analyst Comments

Neurogene (NGNE) PT Lowered to $45 at BMO CapitalNovember 19, 2024 4:02 PM